Ascletis Pharma (HKG:1672) said the first participant has been dosed in a global Phase III clinical program for ASC30, an oral drug being developed for long-term weight management and diabetes.
The program comprises two late-stage trials involving about 4,600 participants across the U.S., Europe and Canada to assess the drug's effectiveness, safety and tolerability, according to a Sunday Hong Kong bourse filing.
Shares of the company plunged over 5% in Monday's trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.